Literature DB >> 21722934

Immunogenicity of low-pH treated whole viral influenza vaccine.

Fu-Shi Quan1, Zhu-Nan Li, Min-Chul Kim, Dan Yang, Richard W Compans, David A Steinhauer, Sang-Moo Kang.   

Abstract

Low pH treatment of influenza virus hemagglutinin (HA) exposes its relatively conserved stalk domain, suggesting a potential immunogen with capability to induce broader immune responses. Here, we describe characterization, immunogenicity, antigenicity, and protective immunity induced by low pH treated inactivated whole viral vaccine in comparison with the untreated vaccine. The acidic pH treated viral vaccine showed high susceptibility to proteolytic cleavage and low hemagglutination activity indicating conformational changes. Immunization of mice with low pH treated viral vaccine induced lower levels of homologous or heterologous virus-specific binding and neutralizing antibodies compared to the untreated vaccine. Also, low pH treated influenza viral antigen showed lower antigenicity compared to the untreated influenza viral antigen. Lower efficacy of cross-protection against heterosubtypic virus was observed in the low-pH treated vaccine group. The results provide evidence that there is a correlation between protective efficacy and the stability of vaccines.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21722934      PMCID: PMC3152636          DOI: 10.1016/j.virol.2011.05.014

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  38 in total

1.  Activation of influenza A viruses by trypsin treatment.

Authors:  H D Klenk; R Rott; M Orlich; J Blödorn
Journal:  Virology       Date:  1975-12       Impact factor: 3.616

2.  Studies on the structure of the influenza virus haemagglutinin at the pH of membrane fusion.

Authors:  R W Ruigrok; A Aitken; L J Calder; S R Martin; J J Skehel; S A Wharton; W Weis; D C Wiley
Journal:  J Gen Virol       Date:  1988-11       Impact factor: 3.891

Review 3.  The structure and function of the hemagglutinin membrane glycoprotein of influenza virus.

Authors:  D C Wiley; J J Skehel
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

Review 4.  Role of hemagglutinin cleavage for the pathogenicity of influenza virus.

Authors:  D A Steinhauer
Journal:  Virology       Date:  1999-05-25       Impact factor: 3.616

5.  Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies.

Authors:  W Gerhard; J Yewdell; M E Frankel; R Webster
Journal:  Nature       Date:  1981-04-23       Impact factor: 49.962

6.  Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity.

Authors:  Yeu-Chun Kim; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz
Journal:  J Control Release       Date:  2009-10-17       Impact factor: 9.776

7.  Changes in the antigenicity of the hemagglutinin molecule of H3 influenza virus at acidic pH.

Authors:  R G Webster; L E Brown; D C Jackson
Journal:  Virology       Date:  1983-04-30       Impact factor: 3.616

8.  Infectious cell entry mechanism of influenza virus.

Authors:  A Yoshimura; K Kuroda; K Kawasaki; S Yamashina; T Maeda; S Ohnishi
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

9.  Influenza virus-like particles containing M2 induce broadly cross protective immunity.

Authors:  Jae-Min Song; Bao-Zhong Wang; Kyoung-Mi Park; Nico Van Rooijen; Fu-Shi Quan; Min-Chul Kim; Hyun-Tak Jin; Andrew Pekosz; Richard W Compans; Sang-Moo Kang
Journal:  PLoS One       Date:  2011-01-18       Impact factor: 3.240

10.  Electron microscopy of antibody complexes of influenza virus haemagglutinin in the fusion pH conformation.

Authors:  S A Wharton; L J Calder; R W Ruigrok; J J Skehel; D A Steinhauer; D C Wiley
Journal:  EMBO J       Date:  1995-01-16       Impact factor: 11.598

View more
  13 in total

1.  Immunogenicity and protection of oral influenza vaccines formulated into microparticles.

Authors:  Prathap Nagaraja Shastri; Min-Chul Kim; Fu-Shi Quan; Martin J D'Souza; Sang-Moo Kang
Journal:  J Pharm Sci       Date:  2012-06-18       Impact factor: 3.534

2.  Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus.

Authors:  Ki-Hye Kim; Young-Tae Lee; Soojin Park; Yu-Jin Jung; Youri Lee; Eun-Ju Ko; Yu-Jin Kim; Xuguang Li; Sang-Moo Kang
Journal:  Virology       Date:  2019-07-08       Impact factor: 3.616

Review 3.  Virus-like particles as universal influenza vaccines.

Authors:  Sang-Moo Kang; Min-Chul Kim; Richard W Compans
Journal:  Expert Rev Vaccines       Date:  2012-08       Impact factor: 5.217

4.  The osmotic stress response of split influenza vaccine particles in an acidic environment.

Authors:  Hyo-Jick Choi; Min-Chul Kim; Sang-Moo Kang; Carlo D Montemagno
Journal:  Arch Pharm Res       Date:  2013-10-08       Impact factor: 4.946

5.  A novel synthetic receptor-based immunoassay for influenza vaccine quantification.

Authors:  Anwar M Hashem; Caroline Gravel; Aaron Farnsworth; Wei Zou; Michelle Lemieux; Kangwei Xu; Changgui Li; Junzhi Wang; Marie-France Goneau; Maria Merziotis; Runtao He; Michel Gilbert; Xuguang Li
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

6.  A mechanistic study on the destabilization of whole inactivated influenza virus vaccine in gastric environment.

Authors:  Hyo-Jick Choi; Charles F Ebersbacher; Min-Chul Kim; Sang-Moo Kang; Carlo D Montemagno
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

Review 7.  New vaccines against influenza virus.

Authors:  Young-Tae Lee; Ki-Hye Kim; Eun-Ju Ko; Yu-Na Lee; Min-Chul Kim; Young-Man Kwon; Yinghua Tang; Min-Kyoung Cho; Youn-Jeong Lee; Sang-Moo Kang
Journal:  Clin Exp Vaccine Res       Date:  2013-12-18

8.  Development of an enzyme-linked immunoassay for the quantitation of influenza haemagglutinin: an alternative method to single radial immunodiffusion.

Authors:  Jesse Bodle; Erin E Verity; Chi Ong; Kirsten Vandenberg; Robert Shaw; Ian G Barr; Steven Rockman
Journal:  Influenza Other Respir Viruses       Date:  2012-05-15       Impact factor: 4.380

9.  Curdlan sulfate-O-linked quaternized chitosan nanoparticles: potential adjuvants to improve the immunogenicity of exogenous antigens via intranasal vaccination.

Authors:  Shu Zhang; Shengshi Huang; Lu Lu; Xinlei Song; Pingli Li; Fengshan Wang
Journal:  Int J Nanomedicine       Date:  2018-04-18

10.  Antiviral Activities of Hibiscus sabdariffa L. Tea Extract Against Human Influenza A Virus Rely Largely on Acidic pH but Partially on a Low-pH-Independent Mechanism.

Authors:  Yohei Takeda; Yuko Okuyama; Hiroto Nakano; Yasunori Yaoita; Koich Machida; Haruko Ogawa; Kunitoshi Imai
Journal:  Food Environ Virol       Date:  2019-10-16       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.